(Part 6 of 6) Substance Use Disorder: Future Directions Focusing on LA Injectable Buprenorphine

Presenter: Michelle R. Lofwall, MD
Moderator: Ellen F. Eaton, MD
January 24, 2024

Substance use disorders may disproportionately affect people with HIV. It is essential that clinicians who treat patients with HIV recognize the signs of substance use disorder and understand the current treatment options and challenges.

Drug Enforcement Agency certificate holders are now required to complete 8 hours of training on opioids, substance use disorders (SUDs), and pain management. The IAS–USA is excited to support you in meeting these new requirements with a free webinar series comprising 8 hours of training to help you provide the best possible care for your HIV patients! The sixth webinar in the series, presented by Michelle R. Lofwall, MD, and moderated by Ellen F. Eaton, MD, discusses future directions in the treatment of substance use disorder on HIV-related morbidity and mortality, including the management of long-acting injectable therapy for opioid use disorder.